Evidence map›Paper›PMID 9846968›Full record

ArticleThe American journal of pathology1998

Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors.

D R Germolec, J Spalding, H S Yu, G S Chen, P P Simeonova, M C Humble, A Bruccoleri, G A Boorman, J F Foley, T Yoshida and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 202 citations in OpenAlex.

  1. Chronic and acute arsenic exposure enhance EGFR expression via distinct molecular mechanisms.Toxicology in vitro : an international journal published in association with BIBRA · 2020
    Article
  2. Arsenic Stimulates Myoblast Mitochondrial Epidermal Growth Factor Receptor to Impair Myogenesis.Toxicological sciences : an official journal of the Society of Toxicology · 2020
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Overabundance of putative cancer stem cells in human skin keratinocyte cells malignantly transformed by arsenic.Toxicological sciences : an official journal of the Society of Toxicology · 2012
    Article
  14. Arsenic exposure and toxicology: a historical perspective.Toxicological sciences : an official journal of the Society of Toxicology · 2011
    Article
  15. Article
  16. Aberrant immune responses in arsenical skin cancers.The Kaohsiung journal of medical sciences · 2011
    Review
  17. Concentration-dependent cellular responses of arsenic in keratinocytes.The Kaohsiung journal of medical sciences · 2011
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

D R GermolecEnvironmental Immunology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA. germolec@niehs.nih.gov
J Spalding
H S Yu
G S Chen
P P Simeonova
M C Humble
A Bruccoleri
G A Boorman
J F Foley
T Yoshida
M I Luster
National Institute of Environmental Health Sciences · USKaohsiung Medical University · TWNational Institute for Occupational Safety and Health · USNational Institutes of Health · USTokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although numerous epidemiological studies have shown that inorganic arsenicals cause skin cancers and hyperkeratoses in humans, there are currently no established mechanisms for their action or animal models. Previous studies in our laboratory using primary human keratinocyte cultures demonstrated that micromolar concentrations of inorganic arsenite increased cell proliferation via the production of keratinocyte-derived growth factors. As recent reports demonstrate that overexpression of keratinocyte-derived growth factors, such as transforming growth factor (TGF)-alpha, promote the formation of skin tumors, we hypothesized that similar events may be responsible for those associated with arsenic skin diseases. Thus, the influence of arsenic in humans with arsenic skin disease and on mouse skin tumor development in transgenic mice was studied. After low-dose application of tetradecanoyl phorbol acetate (TPA), a marked increase in the number of skin papillomas occurred in Tg.AC mice, which carry the v-Ha-ras oncogene, that received arsenic in the drinking water as compared with control drinking water, whereas no papillomas developed in arsenic-treated transgenic mice that did not receive TPA or arsenic/TPA-treated wild-type FVB/N mice. Consistent with earlier in vitro findings, increases in granulocyte/macrophage colony-stimulating factor (GM-CSF) and TGF-alpha mRNA transcripts were found in the epidermis at clinically normal sites within 10 weeks after arsenic treatment. Immunohistochemical staining localized TGF-alpha overexpression to the hair follicles. Injection of neutralizing antibodies to GM-CSF after TPA application reduced the number of papillomas in Tg.AC mice. Analysis of gene expression in samples of skin lesions obtained from humans chronically exposed to arsenic via their drinking water also showed similar alterations in growth factor expression. Although confirmation will be required in nontransgenic mice, these results suggest that arsenic enhances development of skin neoplasias via the chronic stimulation of keratinocyte-derived growth factors and may be a rare example of a chemical carcinogen that acts as a co-promoter.

Indexed as

AnimalsAntibodiesArsenicCell DivisionFemaleGranulocyte-Macrophage Colony-Stimulating FactorGrowth SubstancesHumansImmunohistochemistryMiceMice, TransgenicPapillomaReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSkin DiseasesSkin NeoplasmsAntibodiesArsenicGranulocyte-Macrophage Colony-Stimulating FactorGrowth SubstancesRNA, MessengerTetradecanoylphorbol AcetateTransforming Growth Factor alpha

Identifiers

PMID9846968
PMCPMC1866326
OpenAlexW2111522563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.